Get the Stockscreener App
21.68
7.54%
1.52
After Hours:
21.75
0.07
+0.32%
Denali Therapeutics Inc stock is traded at $21.68, with a volume of 1.88M.
It is up +7.54% in the last 24 hours and up +5.40% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
See More
Previous Close:
$20.16
Open:
$20.24
24h Volume:
1.88M
Relative Volume:
1.09
Market Cap:
$3.44B
Revenue:
$1.27M
Net Income/Loss:
$-512.54M
P/E Ratio:
-7.3019
EPS:
-2.9691
Net Cash Flow:
$-422.10M
1W Performance:
+10.50%
1M Performance:
+5.40%
6M Performance:
+32.92%
1Y Performance:
+64.62%
1-Day Range:
$20.20
$21.71
1-Week Range:
$18.96
$21.71
52-Week Range:
$12.31
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
21.68 | 3.20B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Retail Surge: Can Denali Therapeutics Inc withstand a market correction2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pullback Watch: Is Denali Therapeutics Inc stock suitable for long term investingQuarterly Trade Report & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations - Sahm
Pullback Watch: Can Denali Therapeutics Inc withstand a market correctionMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Retail Surge: What are analysts price targets for Denali Therapeutics IncPrice Action & Risk Controlled Swing Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (DNLI) Edition - Stock Traders Daily
How AVLAYAH’s Accelerated Approval and Takeda Exit Will Impact Denali Therapeutics (DNLI) Investors - Sahm
Aug Opening: Is Denali Therapeutics Inc forming higher highs and higher lowsGap Down & Daily Volume Surge Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
Denali Stock Falls as Partner Takeda Ends Collaboration Deal - Yahoo Finance
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Given New $34.00 Price Target at Robert W. Baird - MarketBeat
Denali shares drop after Takeda terminates partnership agreement - Bitget
Denali regains rights to DNL593 from Takeda - The Pharma Letter
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $39 - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9%Here's What Happened - MarketBeat
Takeda Exits Dementia Drug Partnership With Denali TherapeuticsHere's Why - Benzinga
Takeda Breaks Up With Denali, Dumps Dementia Drug - BioSpace
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Regains Full Control Of DNL593 As It Advances Toward Key 2026 Readout - RTTNews
Takeda (TAK) Ends Collaboration on Drug Development with Denali Therapeutics - GuruFocus
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
DNLI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DNLI Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Reclaims DNL593 Rights Concentrating Dementia Drug Risks And Upside - Sahm
Denali Therapeutics Inc. (DNLI) stock price, news, quote and history - Yahoo Finance Singapore
Denali Regains DNL593 Rights After Takeda Collaboration Ends - TipRanks
Denali Therapeutics Regains Full Rights to DNL593 as Takeda Ends 2018 Collaboration - TradingView
Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593 - marketscreener.com
Takeda exits DNL593 deal; Denali (NASDAQ: DNLI) takes full control of FTD-GRN drug - Stock Titan
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - The Manila Times
Takeda exits dementia drug pact, Denali targets trial data by 2026 end - Stock Titan
Aug Opening: Is Denali Therapeutics Inc a turnaround storyQuarterly Market Review & Community Verified Trade Alerts - baoquankhu1.vn
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Market Overview: Will Denali Therapeutics Inc outperform small cap indexesQuarterly Market Review & Weekly High Return Opportunities - baoquankhu1.vn
Pullback Watch: Will Denali Therapeutics Inc benefit from government policy2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - minichart.com.sg
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
Denali Therapeutics Secures $200 Million Royalty Funding - TipRanks
Denali Therapeutics receives $200 million from royalty agreement after FDA approval - Investing.com India
Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA NodWhat's Changed - Yahoo Finance
Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition? - simplywall.st
(DNLI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter SyndromeSlideshow (NASDAQ:DNLI) 2026-03-27 - Seeking Alpha
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):